AI accelerates drug discovery from decades to months as Isomorphic Labs' Drug Design Engine pushes beyond Nobel-Level science
Article excerpt
Highlighted: the sentence this signal was extracted from
AI accelerates drug discovery from decades to months as Isomorphic Labs' drug design engine pushes beyond nobel-level science. Daniel Levi Posted On February 10, 2026 In 2024, Sir Demis Hassabis and John Jumper were awarded the Nobel Prize in Chemistry for AlphaFold, an AI system that solved a fifty-year problem by predicting protein structures at scale. The achievement felt like a finish line for AI-driven biology. AlphaFold rewired structural biology overnight and reshaped how scientists study life at the molecular level. Sixteen months later, that milestone already feels like an early chapter. Key highlights. * Isomorphic Labs unveiled IsoDDE, an AI drug design engine built to run discovery directly on a computer, cutting timelines from years to months * More than doubles AlphaFold 3 performance on the hardest protein - ligand generalization targets * Up to 20x better than Boltz-2 on antibody and biologics benchmarks * Outperforms physics-based gold standards on binding affinity prediction, at a fraction of the cost and time * Identifies drug binding pockets from sequence alone, including sites that took researchers over 15 years to uncover experimentally The Isomorphic Labs drug design engine unlocks a new frontier beyond AlphaFold. This week, Isomorphic Labs released a technical report showing that its internal drug design engine has surpassed AlphaFold 3, the...
Keep reading with a free account
The rest of this article, and every signal for Isomorphic Labs, is in your free account.
